(Total Views: 756)
Posted On: 11/05/2020 5:25:12 PM
Post# of 154066
Good News = Enrollment and FDA Has Unblinded Data
Seems to me that the good info/news from this cc/webcast, is as follows:
1) all indications for Leronlimab remain alive, progressing, no bad news.
2) enrollment rate for s/c Phase III will be increasing, they are actively taking steps for increase. Ohio, the UK and an exec going on the road
3) why did the FDA reqeust and obtain the Phase III s/c interim data? What could be the outcome of the FDA looking at this data? Considering the rate of increase in new covid-19 cases globally, should they have been talking more about the FDA possibly granting some type of immediate access to Leronlimab?
Seems to me that the good info/news from this cc/webcast, is as follows:
1) all indications for Leronlimab remain alive, progressing, no bad news.
2) enrollment rate for s/c Phase III will be increasing, they are actively taking steps for increase. Ohio, the UK and an exec going on the road
3) why did the FDA reqeust and obtain the Phase III s/c interim data? What could be the outcome of the FDA looking at this data? Considering the rate of increase in new covid-19 cases globally, should they have been talking more about the FDA possibly granting some type of immediate access to Leronlimab?
(3)
(0)
